| Serial Number | 79408203 |
| Word Mark | LIGACHEM |
| Filing Date | Tuesday, August 6, 2024 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, August 26, 2025 |
| Registration Number | 7910368 |
| Registration Date | Tuesday, August 26, 2025 |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, June 10, 2025 |
| Goods and Services | Vaccines; food supplements; vitamin preparations; crude medicines for treating cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; nutraceuticals for use as a dietary supplement; biological preparations for medical use for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medical pharmaceuticals for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; chemical preparations for medical use for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; drug delivery agents consisting of compounds that facilitate delivery of pharmaceuticals for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medical molecular diagnostic reagents for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; biopharmaceuticals for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; syrups for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medicated lozenges for pharmaceutical purposes; capsules sold empty for pharmaceuticals; chemico-pharmaceutical preparations for pharmaceutical or medical purposes, namely, for cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; antibodies for medical purposes; medical antibodies, especially antibody conjugates and active ingredients and antibody conjugates; chemical reagents for medical use, especially chemical reagents for linking molecules for medical use; pharmaceutical compositions for use in treatment and prevention of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; plant extracts, other than essential oils, for medicinal purposes; pharmaceutical preparations for cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets; pharmaceutical preparations for the treatment and prevention of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; antibiotics; anti-cancer preparations; mixed vitamin preparations; chemotherapeutics; pharmaceutical preparations for the treatment of rare cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases |
| Indication of Colors claimed | The color(s) orange, dark grey, light grey and black is/are claimed as a feature of the mark. |
| Description of Mark | The mark consists of a DNA symbol design in orange, dark grey and light grey, made using two vertically interlocking hexagons followed by the wording "LigaChem". The left side of the upper hexagon is orange and resembles the letter "L" with light grey horizontal lines on the right, and the left side of the bottom hexagon is comprised of light grey horizontal lines with dark grey on the right resembling the reversed letter "C", all followed by the wording LigaChem in stylized black letters. The color white visible through the mark represents background only and is not part of the mark. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, November 8, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | LigaChem Biosciences Inc. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Party Name | LigaChem Biosciences Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Party Name | LigaChem Biosciences Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Event Date | Event Description |
| Thursday, October 31, 2024 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, November 8, 2024 | LIMITATION FROM ORIGINAL APPLICATION ENTERED |
| Tuesday, November 12, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, November 12, 2024 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, February 12, 2025 | ASSIGNED TO EXAMINER |
| Friday, February 14, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, February 19, 2025 | WITHDRAWN FROM PUB - SENIOR ATTORNEY REQUEST |
| Wednesday, February 19, 2025 | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
| Thursday, February 20, 2025 | NON-FINAL ACTION WRITTEN |
| Friday, February 21, 2025 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Thursday, March 27, 2025 | REFUSAL PROCESSED BY MPU |
| Thursday, March 27, 2025 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Tuesday, April 8, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, April 8, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, April 8, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Saturday, April 12, 2025 | REFUSAL PROCESSED BY IB |
| Wednesday, May 7, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, June 4, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, June 10, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, June 10, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, August 26, 2025 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, August 26, 2025 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Wednesday, November 26, 2025 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |